Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Operating Expenses (2022 - 2025)

Taysha Gene Therapies' Operating Expenses history spans 4 years, with the latest figure at $34.0 million for Q3 2025.

  • For Q3 2025, Operating Expenses rose 22.89% year-over-year to $34.0 million; the TTM value through Sep 2025 reached $108.4 million, up 11.01%, while the annual FY2024 figure was $99.8 million, 13.54% up from the prior year.
  • Operating Expenses for Q3 2025 was $34.0 million at Taysha Gene Therapies, up from $28.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $56.5 million in Q4 2022 and bottomed at $19.8 million in Q4 2023.
  • The 4-year median for Operating Expenses is $25.8 million (2023), against an average of $29.2 million.
  • The largest annual shift saw Operating Expenses tumbled 64.85% in 2023 before it skyrocketed 31.86% in 2024.
  • A 4-year view of Operating Expenses shows it stood at $56.5 million in 2022, then crashed by 64.85% to $19.8 million in 2023, then rose by 10.6% to $22.0 million in 2024, then skyrocketed by 54.98% to $34.0 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Operating Expenses are $34.0 million (Q3 2025), $28.7 million (Q2 2025), and $23.7 million (Q1 2025).